COMMUNIQUÉS West-GlobeNewswire

Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
27/10/2026
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately [...]
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
27/10/2026
BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Acquisition adds [...]
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
27/10/2026
CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies [...]
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
27/10/2026
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 Company on track to [...]
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
27/10/2026
LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster [...]
BillionToOne to Participate in Two Upcoming Investor Conferences
27/10/2026
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Candel Therapeutics to Present at November Investor Conferences
27/10/2026
NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Human Appeal’s Winter Comedy Tour returns for the 12th year running in aid of orphaned children
27/10/2026
Guz Khan, Tez Ilyas, Kae Kurd, Aatif Nawaz, Prince Abdi, Ali Official, Smash Bengali, Riaad Moosa, and Mic Diesel join this year’s UK tour in support of orphan sponsorship programmes worldwide MANCHESTER, United Kingdom [...]
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
27/10/2026
All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests Four of five completed patients (80%) were negative on highly sensitive [...]
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
27/10/2026
All 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage [...]
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
27/10/2026
Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder Vancouver, Canada, Oct. 27, 2026 (GLOBE NEWSWIRE) -- [...]
Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System
27/10/2026
ELMNT IR also became the first account on the West Coast, marking a geographic expansion which aligns with the Company’s Full Market Release strategy. The Company believes the OBLs represent a rapidly growing healthcare [...]
Onconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
27/10/2026
Echo Tabletop Priced at $11,950 and Echo Full Body at $59,950; First Production Run of 250 Units Available for 2027 Delivery; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary [...]
NEXGEL Regains Compliance with Nasdaq Listing Requirement
27/10/2026
LANGHORNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to [...]
Pyxis Oncology to Present Micvotabart Pelidotin (MICVO) Phase 1 Monotherapy Data in Late-Breaking Oral Presentation and Two Poster Presentations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
27/10/2026
BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a late-breaking oral [...]
Vanquish Brands Announces 2026 Financial Results Estimated to Achieve a 152% 3-Year Annualized Revenue Growth Rate Driven by Its Flagship Brand Pistol and Paris
27/10/2026
Record Performance Results Driven by Increased Demand, Expansion of Nationwide Distribution, Product Innovation and Brand Recognition AGASSIZ, British Columbia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Vanquish Holdings Inc [...]
Syncromune Reports Long-Term Data from Phase 1 Study in Metastatic Prostate Cancer with Investigational SYNC-T Therapy SV-102
27/10/2026
Data support potential for highly differentiated clinical impact for patients suffering from metastatic prostate cancer 50% of patients who achieved a complete response (n=6) remain disease-free more than two years [...]
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
27/10/2026
Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journal Statistically significant improvement in [...]
NorthStar Day Program, First of Its Kind in the Southeast, to Open in Palm Beach Gardens on November 4, 2026
27/10/2026
Innovative multidisciplinary program brings education, therapy, psychiatry and behavioral health services together under one roof for neurodivergent children ages 5–12 PALM BEACH GARDENS, Fla., Oct. 27, 2026 (GLOBE [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum